Screening Libraries Diversified at BOC Sciences for Medicinal Chemistry Research
To meet the newly arising needs in the field of drug discovery, BOC Sciences announced to further diversify its screening libraries for researchers engaged with medicinal chemistry research on August 13, 2019. Previously, this company has established a trouble-shooting platform that covers nearly the whole drug R&D process from lead discovery, compound synthesis and purification to formulation and fabrication.
Having long been known to be an extremely complex process, drug discovery is characterized by long development period, numerous investment, and high failure rate. Fortunately, with the advance of science and technology, in particular, artificial intelligence, an increasingly diversified collection of screening libraries are created and used in modern compound screening.
“Finding the most suitable drug candidate is of paramount importance, but is by no means easy task,” says Mr. Barron Jones, the Marketing Chief of BOC Sciences. “Prior to the debut of screening libraries, researchers need to test and measure the therapeutic potentials of numerous compounds before finally specifying a few blockbuster drug candidates that might be a good ‘hit’ for a certain disease target. But high-throughput screening has made this process simpler, and less time is required, too.”
Although there are already some well-established compound libraries that could be used instantly, sometimes new libraries need to be specially designed to serve certain purposes, using software tools and data formatting systems like SMILES or SDF. “Before a custom library design, we will figure out the general needs of our customers and then choose the most suitable approach to library design based on theories. Recently, there are two new trends: first, the demand for screening collections that are biased towards certain biological targets is on a rise; second, the value of screening libraries of existing drugs also starts to be recognized as they could lead to new treatments when operated by different mechanisms,” Mr. Jones continues to add.
In addition to high-throughput screening, other libraries or methods like fragment-based drug design (FBDD) and activity-based libraries are also rapidly evolved and more frequently used. At BOC Sciences, libraries enriched with privileged chemotypes that target kinases, nuclear hormone receptors, G-protein coupled receptors (GPCRs), ion channels and CNS targets are available. For more information about BOC Sciences’ screening libraries, please visit: https://www.solutions.bocsci.
About BOC Sciences
During the last decade and more, BOC Sciences has been striving to offer strategies and solutions to assist industry’s most pressing drug R&D issues. With this mission, it provides comprehensive medicinal chemistry and drug testing service, custom synthesis, analysis/purification, formulation services for pharmaceutical companies engaged in drug discovery and research.